The Avicena Group, Inc. (Avicena) is a biotechnology company focused on developing and commercializing novel, high-value products that improve the lives of patients by regulating critical cellular energy processes. The company has developed two proprietary platform technologies; one to address cellular energy modulation; and one to address cellular energy transport. Together, these platforms provide the basis for the company’s extensive portfolio of innovative, patent-protected pharmaceutical and dermaceutical products. With regard to its lead pharmaceutical programs, the company’s efforts are focused on orphan drugs for neurodegenerative and neuromuscular diseases.